

## RESEARCH ARTICLE

# Reduced neutrophil granular proteins and post-treatment modulation in tuberculous lymphadenitis

Gokul Raj Kathamuthu<sup>1,2\*</sup>, Kadar Moideen<sup>1</sup>, Rathinam Sridhar<sup>3</sup>, Dhanaraj Baskaran<sup>2</sup>, Subash Babu<sup>1,4</sup>

**1** National Institutes of Health-NIRT-International Center for Excellence in Research, Chennai, India, **2** National Institute for Research in Tuberculosis (NIRT), Chennai, India, **3** Government Stanley Medical Hospital, Chennai, India, **4** Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

\* [gokul.r@nirt.res.in](mailto:gokul.r@nirt.res.in)



## Abstract

### Background

Neutrophils are important for host innate immune defense and mediate inflammatory responses. Pulmonary tuberculosis (PTB) is associated with increased neutrophil granular protein (NGP) levels in the circulation. However, the systemic levels of neutrophil granular proteins were not examined in tuberculous lymphadenitis (TBL) disease.

### Methods

We measured the systemic levels of NGP (myeloperoxidase [MPO], elastase and proteinase 3 [PRTN3]) in TBL and compared them to latent tuberculosis (LTB) and healthy control (HC) individuals. We also measured the pre-treatment (Pre-T) and post-treatment (Post-T) systemic levels of neutrophil granular proteins in TBL individuals upon anti-tuberculosis treatment (ATT) completion. In addition, we studied the correlation and discriminatory ability of NGPs using receiver operating characteristic (ROC) analysis.

### Results

Our data suggests that systemic levels of NGPs (MPO, PRTN3, elastase) were significantly reduced in TBL individuals compared to LTB and HC individuals. Similarly, after ATT, the plasma levels of MPO and elastase but not PRTN3 were significantly elevated compared to pre-treatment levels. NGPs (except PRTN3) were positively correlated with absolute neutrophil count of TBL, LTB and HC individuals. Further, NGPs were able to significantly discriminate TBL from LTB and HC individuals.

### Conclusion

Hence, we conclude reduced neutrophil granular protein levels might be associated with disease pathogenesis in TBL.

## OPEN ACCESS

**Citation:** Kathamuthu GR, Moideen K, Sridhar R, Baskaran D, Babu S (2021) Reduced neutrophil granular proteins and post-treatment modulation in tuberculous lymphadenitis. PLoS ONE 16(6): e0253534. <https://doi.org/10.1371/journal.pone.0253534>

**Editor:** Frederick Quinn, The University of Georgia, UNITED STATES

**Received:** March 15, 2021

**Accepted:** June 7, 2021

**Published:** June 21, 2021

**Copyright:** This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the [Creative Commons CC0](https://creativecommons.org/licenses/by/4.0/) public domain dedication.

**Data Availability Statement:** All relevant data are within the manuscript and its [Supporting Information](#) files.

**Funding:** This work was supported by the Division of Intramural Research, NIAID, NIH.

**Competing interests:** The authors have declared that no competing interests exist.

## Introduction

Tuberculosis (TB) is a leading cause of infection with 1.2 million deaths and 10 million active cases were reported globally in the year 2019 [1]. *Mycobacterium tuberculosis* (Mtb) primarily affects the lung parenchyma (active or pulmonary TB), or involves extrapulmonary dissemination. Extra pulmonary TB (EPTB) cases represent 16% among the 7.1 million incident cases reported by World Health Organization (WHO) in the year 2019 [1]. Among them, tuberculous lymphadenitis (TBL) is the most common form with a high female to male ratio was observed [2–4]. In India, EPTB comprises 20% of all types of TB infection; whereas, TBL disease is observed in nearly 35% of EPTB cases with cervical lymph nodes (60 to 90% of cases) being the most commonly affected [5]. Both innate and adaptive immunity, especially CD4<sup>+</sup> T cells and type 1 cytokines are important for host protection [6]. However, recent investigation disclosed the potential role of neutrophils in host immune response during TB infection [7, 8].

Activation of granulocytes is a hallmark of TB disease and neutrophils were assumed to play a significant role. Since, neutrophils are the most abundant polymorphonuclear (PMN) leukocytes among white blood cells and their deficit (either inherited or acquired) leads to severe infections. In addition, they also play a vital function in eliciting immunity against bacterial pathogens [9, 10]. They are the first line of immune defense which are regulated by diverse pro and anti-inflammatory cytokines, chemokines, alarmins (such as S100A8/A9 proteins) and intrinsically expressed microRNAs (such as microRNA-223) after being recruited by tissue-resident cells [11–15]. Neutrophil granules exhibit antimicrobial activity either by one of these mechanisms such as degranulation, oxidative killing of phagocytosis from infected macrophages, reactive oxygen species and neutrophil extracellular traps (NETs) and thereby eradicates an invading pathogen [16, 17]. It is also important for magnifying inflammatory responses [18]. Some of the elements which are released by neutrophils after respiratory burst are elastase, collagenase and myeloperoxidase (MPO) and they often comprehensively harm both bacterial and host cells extracellularly [19, 20].

It was also shown in zebrafish model, polymorphonuclear leukocytes has the potential ability to kill *Mycobacterium marinum* after being infected [21]. In humans, neutrophil numbers were positively correlated with active TB disease [22, 23] and able to contribute to lung pathology in animal models [24, 25]. Similarly, both MPO and eosinophil peroxidase present in the immune cells might potentially support the host isoniazid (INH) activation. This INH treatment was greatly effective in controlling the development of active TB disease by restricting LTB infection [26, 27]. Henceforth, neutrophils potentially compose an effector cell population which can undertake both antimycobacterial and immunopathological functions during active Mtb disease [28]. However, the function of neutrophil granular proteins (NGP) in TBL disease is not well-known. In addition, whether these NGPs have the ability to serve as biomarkers for TBL disease upon differentiating LTB and HCs has not been studied. Hence, we have examined the circulating levels of NGP (MPO, PRTN3 and elastase) in TBL individuals and compared them with LTB and HC individuals. Our results show that NGPs were significantly diminished in TBL individuals and their levels were reversed significantly after the completion of anti-tuberculosis treatment (ATT).

## Materials and methods

### Ethics

The present study was approved by Internal Ethics Committees (IEC) of National Institute of Research in Tuberculosis (NIRTIEC2010007) and informed written consent form was obtained from all the study individuals. The origin of the study data are given in [S1 Table](#).

## Study subjects

Totally, 88 blood samples were collected, 44 with tuberculous lymphadenitis (TBL) and 44 with latent tuberculosis (LTB) disease. The sample size were calculated based on our previous publications [29, 30] and all the study samples were collected from Chennai, Tamil Nadu, India. TBL individuals were diagnosed as positive either on the basis of excision biopsy (i.e affected lymph nodes) or Xpert or culture positive for *Mycobacterium tuberculosis* (Mtb) in the infected lymph node tissues. During enrolment, TBL individuals did not have any previous TB complication or administered with any anti-TB treatment (ATT). TBL individuals were treated with standard ATT for 6 months (Isoniazid, Rifampicin, Ethambutol, Pyrazinamide were given for 2 months followed by Isoniazid and Rifampicin for 4 months) and upon treatment completion, blood samples were collected once again. LTB group were diagnosed based on the positivity for both tuberculin skin test (TST) and QuantiFERON TB-Gold in tube enzyme-linked immunosorbent assay (ELISA). LTB individuals were negative for sputum smear and devoid of any pulmonary symptoms and have normal chest x-ray. A positive TST result was determined as an induration of at least 12 mm in diameter to reduce false positivity due to exposure to environmental mycobacteria. HCs were defined by the negative results on both Mantoux skin test (induration diameter <5 mm upon given with 2 tuberculin units of purified protein derivative [Staten's Serum Institute]) and QuantiFERON-TB Gold in Tube (Qiagen) assay. All individuals had been vaccinated with Calmette-Guerin; they were negative for human immunodeficiency virus infection and pulmonary tuberculosis and not under any steroid medications.

## Plasma collection and measurement of hematological parameters

The peripheral blood (10 ml) samples were collected and plasma was separated after centrifugation at 1,460 Relative Centrifugal Force (RCF) or G-Force for 10 min at 4°C. The plasma were aliquoted and stored at -80°C until further use. The hematological parameters between the study population were measured using an AcT 5 Diff hematology analyzer.

## Measurement of neutrophil granular proteins

The circulating levels of myeloperoxidase (MPO), proteinase3 (PRTN3) (duo set kits from R&D Systems, Minneapolis, MN, USA) and elastase (Hycult biotech) were measured using ELISA. The lowest detection limit are MPO-62.5pg/ml, PRTN3-15.625pg/ml and elastase 0.4ng/ml.

## Statistical analysis

Statistical analysis were performed using Graph-Pad PRISM (Version 8, GraphPad Software, Inc., San Diego, CA, USA). Statistical differences were evaluated using Kruskal-Wallis test as well as Wilcoxon matched-pair test and geometric means (GM) were used for the measurements of central tendency. Correlations were examined using Spearman rank correlation test. Receiver operator characteristic (ROC) analysis were carried out to test the power of each NGPs to distinguish TBL from LTB individuals. They were used to measure the sensitivity (true positives with infection) and specificity (true negatives without infection) of the TBL compared to LTB and HC individuals.

## Results

### Demographics

The detailed demographics of the study population are shown in [Table 1](#).


Table 1. Demographics of the study population.

Study Demographics	TBL BL	TBL PT	LTB	HC
No. of subjects recruited	44	44	44	44
Gender (Male / Female)	21/23	21/23	22/22	23/21
Median Age (Range)	27 (18–51)	27 (18–51)	36 (22–65)	36.7 (19–63)
Median Height (cm)	160 (140–168)	160 (140–168)	163 (146–175)	161 (144–178)
Median Weight (kg)	45 (34–68.6)	45 (34–68.6)	59 (37–80)	62 (40–84)
QuantIFERON-TB Gold	Not done	Not done	Positive	Negative
Tuberculin skin test (mm)	Not done	Not done	<12	>12
Absolute Neutrophil Numbers	4002.8 (696–6879.6)	3647.58 (1227.6–6879.6)	4302.9 (2054.4–9779)	5028.9 (2562–9439.3)

<https://doi.org/10.1371/journal.pone.0253534.t001>

## TBL is associated with reduced neutrophil granular proteins

To examine the systemic levels of neutrophil granular proteins in TBL, we measured the circulating levels of MPO, PRTN3 and elastase in TBL, LTB and HC individuals (Fig 1). As shown



**Fig 1. TBL is associated with diminished systemic levels of neutrophil granular proteins and reversal after the completion of ATT.** (A) The circulating levels of myeloperoxidase (MPO), proteinase 3 (PRTN 3) and elastase from TBL (n = 44), LTB (n = 44) and HC (n = 44) individuals were analyzed by ELISA. Data are shown as scatter plots, with the bars representing the geometric means. P values were calculated using the Kruskal–Wallis test test. (B) The circulating levels of NGPs (MPO, PRTN3, elastase) from TBL individuals were measured at baseline (pre-treatment [pre-T]) and after the completion of 6 months of ATT (post-treatment [post-T]) by ELISA. P values were calculated using the Wilcoxon matched pair test.

<https://doi.org/10.1371/journal.pone.0253534.g001>

in Fig 1A, the circulating levels of MPO was significantly lower in TBL compared to LTB (GM of TBL is 3.022 ng/ml versus 9.819 ng/ml in LTB) and HC (GM of TBL is 3.022 ng/ml versus 35.45 ng/ml in HC) individuals. Similarly, the circulating levels of PRTN3 was also significantly diminished in TBL upon comparison with LTB (GM of TBL is 2.626 ng/ml versus 13.09 ng/ml in LTB) and HC (GM of TBL is 2.626 ng/ml versus 18.33 ng/ml in HC) individuals. Finally, the circulating levels of elastase was significantly diminished in TBL upon comparison with LTB (GM of TBL is 778.3 ng/ml versus 1666 ng/ml in LTB) and HC (GM of TBL is 778.3 ng/ml versus 6063 ng/ml in HC) individuals. Thus, we show TBL individuals show reduced circulating levels of NGPs as opposed to LTB and HC individuals.

### Post treatment modulation of neutrophil granular proteins in TBL

To examine the effect of anti-tuberculosis treatment (ATT) on neutrophil granular proteins (MPO, PRTN3, elastase), we have analyzed their pre and post-treatment systemic levels among TBL individuals (Fig 1B). We show after ATT completion, the circulating levels of MPO (GM of TBL pre-T is 3.022 ng/ml versus 3.722 ng/ml in post-T) and elastase (GM of TBL pre-T is 778.3 ng/ml versus 1536 ng/ml in post-T) were significantly increased in post-treatment TBL individuals compared to pre-treatment individuals. However, in contrast, we did not observe any significant changes in PRTN3 circulating levels (GM of TBL pre-T is 2.626 ng/ml versus 2.683 ng/ml in post-T) between pre and post-treatment TBL individuals. Hence, successful completion of ATT is associated with significantly enhanced circulating levels of NGPs (except PRTN3).

### Correlation analysis of neutrophil granular proteins


Further, we also studied the association of absolute neutrophil counts with circulating levels of NGPs (MPO, PRTN3, elastase) among TBL, LTB and HC individuals (Fig 2). As shown in Fig 2A, upon correlation analysis of NGP levels with absolute neutrophil counts, MPO ( $r = 0.3023$ ;  $P = 0.0004$ ) and elastase ( $r = 0.1758$ ;  $P = 0.0446$ ) did possess significant positive (except PRTN3) correlation between the study groups.

### ROC analysis of neutrophil granular proteins

In order to understand the discriminatory power of NGPs in discriminating TBL from LTB and HC individuals, we have executed the receiver operator characteristic (ROC) curve analysis of MPO, elastase, PRTN3 between TBL versus LTB and HC individuals. As shown in Fig 2B and 2C, proteinase 3 [sensitivity-100% and specificity-97.67%,  $P < 0.0001$ , AUC = 0.9767; sensitivity-100% and specificity-100%,  $P < 0.0001$ , area under the curve (AUC) = 1] showed a greatest (followed by MPO [sensitivity-100% and specificity-88.64%,  $P < 0.0001$ , AUC = 0.9458; sensitivity-100% and specificity-100%,  $P < 0.0001$ , AUC = 1] and elastase [sensitivity-79.55% and specificity-72.73%,  $P < 0.0001$ , AUC = 0.7893; sensitivity-97.73% and specificity-97.73%,  $P < 0.0001$ , AUC = 0.9866]) significant sensitivity and specificity and AUC in discriminating TBL from LTB and HC individuals.

### Discussion

Neutrophils plays an important role in initiation, regulation or suppression against both innate and adaptive immune effector functions [31–33]. They also facilitate an immune priming of Mtb via phagocytized bacteria to enter through the migratory dendritic cells and accelerates their trafficking into lymph nodes [34]. In addition, both animal and human studies indicate that neutrophil levels were correlated with disease burden and pathology, which are a common



**Fig 2. Positive significant correlation was observed among NGPs.** (A) The circulating levels of NGPs (MPO, PRTN3, elastase) from all study (TBL, LTB and HC) individuals were correlated with their absolute neutrophil counts (ANC). Both  $r$  and  $p$  values were measured using Spearman rank correlation test at 95% confidence intervals. (B and C) ROC analysis (to estimate the sensitivity, specificity and area under the curve) was performed using the circulating levels of NGPs to understand the discriminatory ability to distinguish TBL from LTB and HC individuals.

<https://doi.org/10.1371/journal.pone.0253534.g002>

phenomenon of TB disease [35–37]. Ex-vivo analysis of neutrophil-depleted whole blood has a 3.1-fold poor ability to control *Mtb* infection [38, 39]. In contrast, neutrophils may also induce disease pathology through necrotic cell death rather than phagocytosis and degradation, therefore fails to kill *Mtb* [40, 41]. Previous data also suggest that PTB individuals are associated with enhanced systemic levels of neutrophil and eosinophil granular proteins compared to LTB individuals and significantly modulated after ATT completion indicating the role of enhanced neutrophil activity in PTB disease [42].

Myeloperoxidase (MPO) is a major protein in neutrophils and it composes 5% of the azurophilic granules [43]. It plays a significant role in respiratory burst upon neutrophil activation [43] and assists in the conversion of hydrogen peroxide ( $H_2O_2$ ) to hypochlorous acid (HOCl) which is an important molecule for host immune defense [43, 44]. Our data show that TBL individuals exhibit significantly diminished circulating levels of MPO upon comparison with LTB and HC individuals and were modulated after the treatment completion. We therefore postulate that decreased levels of MPO could in turn favors the disease severity in TB infected individuals compared to LTB and HC groups. In addition, our data demonstrates that the

plasma levels of MPO were significantly altered (elevated) upon completion of ATT in TBL individuals; suggesting *Mtb* bacteria might regulate the neutrophil granular proteins in TBL disease.

Similarly, our data also suggest the plasma levels of PRTN3 and elastase were significantly diminished in TBL individuals compared to LTB and HC individuals. However, in contrast, only elastase levels were significantly increased after the completion of ATT. Elastase, another crucial factor of NETs which contributes in the degradation of bacterial virulence factors and aids in the translocation of granules present in the cytoplasm to the nucleus and chromatin decondensation results in NETosis [45]. In addition, they can activate the macrophages and enhances their ability to kill intracellular pathogens and also helps in releasing increased amount of proinflammatory cytokines for protective immune response [46, 47]. Similarly, PRTN3 present in the azurophil granules of mature cell and exists in the secretory vesicles which are present near the cell surface [48, 49]. They also regulate various cytokine functions associated with metabolism as well as inflammasome complex which are responsible for elevated production and/or alteration of pro-inflammatory and decreased anti-inflammatory cytokines [50–52]. Thus, our data on PRTN3 and elastase suggests that the diminished levels of these granular proteins are a hallmark of TBL disease than LTB and HCs. Hence, we assume that PRTN3 might associate with inflammatory process; therefore, it could possibly require prolonged time to significantly modulate after treatment completion in TBL individuals.

Further, we also studied the association of absolute neutrophil counts (ANC) with NGP levels of respective TBL individuals and these proteins display significant positive association between TBL, LTB and HCs. Finally, our data show that NGPs potentially discriminate TBL from LTB and HC individuals with superior (sensitivity, specificity and AUC) distinction was observed for HCs than LTB; hence, they could act as a potential discriminatory marker. Thus, our future idea is to examine the antigen specific levels of NGPs in the affected lymph nodes of TBL individuals which possibly may disclose an essential insight into the mechanism of those markers in inducing protective or pathogenic immune responses against TBL disease.

## Supporting information

**S1 Table. Origin of the study data.**

(DOC)

## Acknowledgments

The authors thank the Indian Council of Medical Research (ICMR), New Delhi, India for the ICMR-PDF award to Gokul Raj Kathamuthu. We also thank V. Rajesh Kumar of NIH-NIRT-ICER and the staff of the Department of Clinical Research, NIRT, Government Stanley Hospital, Government General Hospital and Government Kilpauk Medical Hospital, Chennai, India, for valuable assistance in recruiting the patients for this study.

## Author Contributions

**Conceptualization:** Gokul Raj Kathamuthu.

**Data curation:** Gokul Raj Kathamuthu.

**Formal analysis:** Gokul Raj Kathamuthu.

**Funding acquisition:** Subash Babu.

**Investigation:** Gokul Raj Kathamuthu, Kadar Moideen.

**Project administration:** Dhanaraj Baskaran, Subash Babu.

**Resources:** Rathinam Sridhar, Dhanaraj Baskaran.

**Software:** Subash Babu.

**Supervision:** Subash Babu.

**Validation:** Subash Babu.

**Visualization:** Subash Babu.

**Writing – original draft:** Gokul Raj Kathamuthu.

**Writing – review & editing:** Subash Babu.

## References

1. WHO (World Health Organization). Global Tuberculosis Report. (WHO, 2020). [https://www.who.int/tb/publications/global\\_report/en/](https://www.who.int/tb/publications/global_report/en/).
2. Catano JC, Robledo J. Tuberculous Lymphadenitis and Parotitis. *Microbiol Spectr*. 2016; 4(6). <https://doi.org/10.1128/microbiolspec.TNMI7-0008-2016> PMID: 28084205
3. Fontanilla JM, Barnes A, von Reyn CF. Current diagnosis and management of peripheral tuberculous lymphadenitis. *Clin Infect Dis*. 2011; 53(6):555–562. <https://doi.org/10.1093/cid/cir454> PMID: 21865192
4. Holden IK, Lillebaek T, Andersen PH, Bjerrum S, Wejse C, Johansen IS. Extrapulmonary tuberculosis in Denmark from 2009 to 2014; Characteristics and predictors for treatment outcome. *Open Forum Infect Dis*. 2019; 6(10):ofz388. <https://doi.org/10.1093/ofid/ofz388> PMID: 31660351
5. Arora VK, Chopra KK. 2007. Extra pulmonary tuberculosis. *Indian J Tuberc*. 54:165–167. PMID: 18072528
6. Ernst JD. The immunological life cycle of tuberculosis. *Nat Rev Immunol*. 2012; 12(8):581–591. <https://doi.org/10.1038/nri3259> PMID: 22790178
7. Lerner TR, Borel S, Gutierrez MG. The innate immune response in human tuberculosis. *Cell Microbiol*. 2015; 17(9):1277–1285. <https://doi.org/10.1111/cmi.12480> PMID: 26135005
8. Borkute RR, Woelke S, Pei G, Dorhoi A. Neutrophils in tuberculosis: Cell biology, cellular networking and multitasking in host defense. *Int J Mol Sci*. 2021; 22(9):4801. <https://doi.org/10.3390/ijms22094801> PMID: 33946542
9. Klein C. Genetic defects in severe congenital neutropenia: emerging insights into life and death of human neutrophil granulocytes. *Annu Rev Immunol*. 2011; 29:399–413. <https://doi.org/10.1146/annurev-immunol-030409-101259> PMID: 21219176
10. Jenne CN, Wong CH, Zemp FJ, McDonald B, Rahman MM, Forsyth PA, et al. Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps. *Cell Host Microbe*. 2013; 13:169–180. <https://doi.org/10.1016/j.chom.2013.01.005> PMID: 23414757
11. Cassatella MA, Östberg NK, Tamassia N, Soehnlein O. Biological Roles of Neutrophil-Derived Granule Proteins and Cytokines. *Trends Immunol*. 2019; 40(7):648–664. <https://doi.org/10.1016/j.it.2019.05.003> PMID: 31155315
12. Borregaard N. Neutrophils, from marrow to microbes. *Immunity*. 2010; 3(5):657–670. <https://doi.org/10.1016/j.immuni.2010.11.011> PMID: 21094463
13. Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. *Nat Rev Immunol*. 2013; 13:159–175. <https://doi.org/10.1038/nri3399> PMID: 23435331
14. Gopal R, Monin L, Torres D, Slight S, Mehra S, McKenna KC, et al. S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during tuberculosis. *Am J Respir Crit Care Med*. 2013; 188(9):1137–1146. <https://doi.org/10.1164/rccm.201304-0803OC> PMID: 24047412
15. Dorhoi A, Iannaccone M, Farinacci M, Fae KC, Schreiber J, Moura-Alves P, et al. MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. *J Clin Invest*. 2013; 123(11):4836–4848. <https://doi.org/10.1172/JCI67604> PMID: 24084739
16. Sorensen OE, Borregaard N. Neutrophil extracellular traps—the dark side of neutrophils. *J Clin Invest*. 2016; 126(5):1612–1620. <https://doi.org/10.1172/JCI84538> PMID: 27135878
17. Yang CT, Cambier CJ, Davis JM, Hall CJ, Crosier PS, Ramakrishnan L. Neutrophils exert protection in the early tuberculous granuloma by oxidative killing of mycobacteria phagocytosed from infected macrophages. *Cell Host Microbe*. 2012; 12:301–312. <https://doi.org/10.1016/j.chom.2012.07.009> PMID: 22980327



18. Pham CT. Neutrophil serine proteases fine-tune the inflammatory response. *Int J Biochem Cell Biol*. 2008; 40(6–7):1317–1333. <https://doi.org/10.1016/j.biocel.2007.11.008> PMID: 18180196
19. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. *Scienc*. 2004; 303(5661):1532–1535. <https://doi.org/10.1126/science.1092385> PMID: 15001782
20. Gupta S, Kaplan MJ. The role of neutrophils and NETosis in autoimmune and renal diseases. *Nat Rev Nephrol*. 2016; 12:402–413. <https://doi.org/10.1038/nrneph.2016.71> PMID: 27241241
21. Yang CT, Cambier CJ, Davis JM, Hall CJ, Crosier PS, Ramakrishnan L. Neutrophils exert protection in the early tuberculous granuloma by oxidative killing of mycobacteria phagocytosed from infected macrophages. *Cell Host Microbe*. 2012; 12(3):301–312. <https://doi.org/10.1016/j.chom.2012.07.009> PMID: 22980327
22. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. *Nature*. 2010; 466(7309):973–977. <https://doi.org/10.1038/nature09247> PMID: 20725040
23. Eum SY, Kong JH, Hong MS, Lee YJ, Kim JH, Hwang SH, et al. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. *Chest*. 2010; 137(1):122–128. <https://doi.org/10.1378/chest.09-0903> PMID: 19749004
24. Dorhoi A, Kaufmann SH. Versatile myeloid cell subsets contribute to tuberculosis-associated inflammation. *Eur J Immunol*. 2015; 45(8):2191–2202. <https://doi.org/10.1002/eji.201545493> PMID: 26140356
25. Dallenga T, Linnemann L, Paudyal B, Repnik U, Griffiths G, Schaible UE. Targeting neutrophils for host-directed therapy to treat tuberculosis. *Int J Med Microbiol*. 2017; 308(1):142–147. <https://doi.org/10.1016/j.ijmm.2017.10.001> PMID: 29055689
26. Denholm JT, McBryde ES. The use of anti-tuberculosis therapy for latent TB infection. *Infect Drug Resist*. 2010; 3:63–72. <https://doi.org/10.2147/idr.s8994> PMID: 21694895
27. Menzies D, Adjibimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four months of Rifampin or nine months of Isoniazid for latent tuberculosis in adults. *N Engl J Med*. 2018; 379:440–453. <https://doi.org/10.1056/NEJMoa1714283> PMID: 30067931
28. Liu CH, Liu H, Ge B. Innate immunity in tuberculosis: host defense vs pathogen evasion. *Cell Mol Immunol*. 2017; 14:963–975. <https://doi.org/10.1038/cmi.2017.88> PMID: 28890547
29. Kathamuthu GR, Moideen K, Banurekha VV, Nair D, Sridhar R, Baskaran D, et al. Altered circulating levels of B cell growth factors and their modulation upon anti-tuberculosis treatment in pulmonary tuberculosis and tuberculous lymphadenitis. *PLoS ONE* 2018; 13(11):e0207404. <https://doi.org/10.1371/journal.pone.0207404> PMID: 30427928
30. Kathamuthu GR, Moideen K, Kumar NP, Sridhar R, Baskaran D, Babu S. Altered systemic levels of acute phase proteins in tuberculous lymphadenitis and modulation after treatment. *PLoS ONE*. 2020; 15(5):e0233426. <https://doi.org/10.1371/journal.pone.0233426> PMID: 32470023
31. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. *Nat Rev Immunol*. 2011; 11(8):519–531. <https://doi.org/10.1038/nri3024> PMID: 21785456
32. Soehnlein O, Steffens S, Hidalgo A, Weber C. Neutrophils as protagonists and targets in chronic inflammation. *Nat Rev Immunol*. 2017; 17(4):248–261. <https://doi.org/10.1038/nri.2017.10> PMID: 28287106
33. Scapini P, Cassatella MA. Social networking of human neutrophils within the immune system. *Blood*. 2014; 124(5):710–719. <https://doi.org/10.1182/blood-2014-03-453217> PMID: 24923297
34. Blomgran R, Ernst JD. Lung neutrophils facilitate activation of naive antigen-specific CD4+ T cells during *Mycobacterium tuberculosis* infection. *J Immunol*. 2011; 186(12):7110–7119. <https://doi.org/10.4049/jimmunol.1100001> PMID: 21555529
35. Niazi MK, Dhulekar N, Schmidt D, Major S, Cooper R, Abeijon C, et al. Lung necrosis and neutrophils reflect common pathways of susceptibility to *Mycobacterium tuberculosis* in genetically diverse, immune-competent mice. *Dis Model Mech*. 2015; 8(9):1141–1153. <https://doi.org/10.1242/dmm.020867> PMID: 26204894
36. Mattila JT, Maiello P, Sun T, Via LE, Flynn JL. Granzyme B-expressing neutrophils correlate with bacterial load in granulomas from *Mycobacterium tuberculosis*-infected cynomolgus macaques. *Cell Microbiol*. 2015; 17(8):1085–1097. <https://doi.org/10.1111/cmi.12428> PMID: 25653138
37. Berry M, Graham C, McNab F, Xu Z, Bloch SAA, Oni T, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. *Nature*. 2010; 466:973–977. <https://doi.org/10.1038/nature09247> PMID: 20725040
38. Martineau AR, Newton SM, Wilkinson KA, Kampmann B, Hall BM, Nawroly N, et al. Neutrophil-mediated innate immune resistance to mycobacteria. *J Clin Invest*. 2007; 117(7):1988–1994. <https://doi.org/10.1172/JCI31097> PMID: 17607367

39. Lowe DM, Demaret J, Bangani N, Nakiwala JK, Goliath R, Wilkinson KA, et al. Differential effect of viable versus necrotic neutrophils on *Mycobacterium tuberculosis* growth and cytokine induction in whole blood. *Front Immunol*. 2018; 9:903. <https://doi.org/10.3389/fimmu.2018.00903> PMID: 29755473
40. Dallenga T, Repnik U, Corleis B, Eich J, Reimer R, Griffiths GW, et al. *M. tuberculosis*-induced necrosis of infected neutrophils promotes bacterial growth following phagocytosis by macrophages. *Cell Host Microbe*. 2017; 22:519–530.e3. <https://doi.org/10.1016/j.chom.2017.09.003> PMID: 29024644
41. Corleis B, Korbel D, Wilson R, Bylund J, Chee R, Schaible UE. Escape of *Mycobacterium tuberculosis* from oxidative killing by neutrophils. *Cell Microbiol*. 2012; 14(7):1109–1121. <https://doi.org/10.1111/j.1462-5822.2012.01783.x> PMID: 22405091
42. Moideen K, Kumar NP, Nair D, Banurekha VV, Bethunaickan R, Babu S. Heightened systemic levels of neutrophil and eosinophil granular proteins in pulmonary tuberculosis and reversal following treatment. *Infect Immun*. 2018; 86(6):e00008–18. <https://doi.org/10.1128/IAI.00008-18> PMID: 29632246
43. Klebanoff SJ. Myeloperoxidase: friend and foe. *J Leukoc Biol*. 2005; 77(5):598–625. <https://doi.org/10.1189/jlb.1204697> PMID: 15689384
44. Aratani Y. Myeloperoxidase: its role for host defense, inflammation, and neutrophil function. *Arch Biochem Biophys*. 2018; 640:47–52. <https://doi.org/10.1016/j.abb.2018.01.004> PMID: 29336940
45. Yipp BG, Kubes P. NETosis: how vital is it? *Blood*. 2013; 122(16):278494. <https://doi.org/10.1182/blood-2013-04-457671> PMID: 24009232
46. Blok DC, Kager LM, Hoogendijk AJ, Lede IO, Rahman W, Afroz R, et al. Expression of inhibitory regulators of innate immunity in patients with active tuberculosis. *BMC Infect Dis*. 2015; 15:98. <https://doi.org/10.1186/s12879-015-0833-z> PMID: 25887604
47. Braian C, Hoge V, Stendahl O. Mycobacterium tuberculosis- induced neutrophil extracellular traps activate human macrophages. *J Innate Immun*. 2013; 5(6):591–602. <https://doi.org/10.1159/000348676> PMID: 23635526
48. Csernok E, Ernst M, Schmitt W, Bainton DF, Gross WL. Activated neutrophils express proteinase 3 on their plasma membrane In vitro and In vivo. *Clin Exp Immunol*. 1994; 95(2):244–250. <https://doi.org/10.1111/j.1365-2249.1994.tb06518.x> PMID: 8306499
49. Witko-Sarsat V, Cramer EM, Hieblot C, Guichard J, Nusbaum P, Lopez S, et al. Presence of proteinase 3 in secretory vesicles: evidence of a novel, highly Mobilizable intracellular Pool distinct from Azurophil granules. *Blood*. 1999; 94(7):2487–2496. PMID: 10498622
50. Sorensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS, et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. *Blood*. 2001; 97(12):3951–3959. <https://doi.org/10.1182/blood.v97.12.3951> PMID: 11389039
51. Ren K, Torres R. Role of interleukin-1beta during pain and inflammation. *Brain Res Rev*. 2009; 60(1):57–64. <https://doi.org/10.1016/j.brainresrev.2008.12.020> PMID: 19166877
52. Popa C, Netea MG, van Riel PLCM, van der Meer JWM, Stalenhoef AFH. The role of TNF $\alpha$  in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. *J Lipid Res*. 2007; 48(4):751–762. <https://doi.org/10.1194/jlr.R600021-JLR200> PMID: 17202130